US Appeals Court Revives Tylenol-Autism Lawsuits
A federal appeals court has reinstated lawsuits claiming Tylenol use during pregnancy is linked to autism, reviving legal pressure on makers.
A federal appeals court has breathed new life into a wave of lawsuits alleging that prenatal use of Tylenol — the ubiquitous acetaminophen painkiller — is connected to autism spectrum disorder in children. The ruling reverses an earlier dismissal and puts the litigation back on track, which is a big deal for anyone holding positions in Johnson & Johnson or Kenvue, the consumer health spinoff that now owns the Tylenol brand.
The core legal argument is that manufacturers failed to adequately warn pregnant consumers about potential developmental risks. That's a classic failure-to-warn claim, and those cases can get expensive fast. Kenvue went public in 2023 and inherited a portfolio of legacy liabilities along with the brand — this ruling is a reminder that those risks are very real and unresolved.
Read more Stocks Slide in Toxic Mix: How to Revive the AI Trade →
For traders, the key question is liability exposure. Mass tort litigation of this kind can drag on for years, but appellate-level reversals signal the courts are taking the science seriously enough to let juries decide. That uncertainty tends to weigh on share prices, especially for a consumer-staples name where the bull case depends on predictable, boring cash flows.
Watch for Kenvue and J&J to respond with legal filings or updated risk disclosures. Any movement on settlement talks would be the real catalyst — either direction. Until then, this story sits in the "known unknown" bucket: real legal risk, unclear dollar amount, long timeline. Position accordingly and keep your stop losses tight.
Continue reading at SeekingAlpha.
